Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06709144Phase 3Active Not Recruiting

Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer

Role: collaborator

NCT03116555Phase 2Unknown

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Role: collaborator

NCT04053205Phase 1Unknown

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Role: collaborator

All 3 trials loaded